Ivan Castellví1, Muriel Elhai2, Cosimo Bruni3, Paolo Airò4, Suzana Jordan5, Lorenzo Beretta6, Veronica Codullo7, Carlo Maurizio Montecucco7, Maria Bokarewa8, Florenzo Iannonne9, Alexandra Balbir10, Vivien M Hsu11, Oliver Distler5, Marco Matucci-Cerinic3, Yannick Allanore2. 1. Universitat Autònoma de Barcelona, Division of Rheumatology and Autoimmune Systemic Diseases, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: icastellvi@santpau.cat. 2. Paris Descartes University, INSERM U1016, Sorbone Paris Cité, Rheumatology A Department, Cochin Hospital, Paris, France. 3. Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy. 4. UO Reumatologia ed Immunologia Clinica Spedali Civili Brescia, Brescia, Italy. 5. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland. 6. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy. 7. Unita Operativa e Cattedra di Reumatologia. Policlinico Sant Matteo, Pavia, Italy. 8. Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Hospital, University of Gothenburg. Gothenburg, Sweden. 9. Rheumatology Unit-DETO, University of Bari. Bari. Italy. 10. B. Shine Rheumatology Unit, Rambam Health Care Campus and Rappaport Faculty of Medicine, Haifa, Israel. 11. Rutgers- Robert Wood Johnson Medical School Scleroderma Program, New Brunswick, United States.
Abstract
OBJECTIVE: To analyze the safety and effectiveness of abatacept (ABA) given in routine care to patients with systemic sclerosis (SSc). METHODS: Retrospective multicenter observational study that enrolled patients with SSc treated with ABA. We collected epidemiological data and clinical outcomes. First, we analyzed the frequency of adverse effects. Secondly, we compared the evolution of different organ manifestations during ABA treatment. We collected data from 6 months before start of therapy to the last follow-up the following parameters: modified Rodnan Skin Score (mRSS), joints, lung and gastrointestinal involvement, concomitant medications, and laboratory tests. RESULTS: Data on twenty-seven patients with SSc were collected (93% females; 67% limited SSc). Rheumatoid arthritis was the most frequent concomitant autoimmune disease. ILD was present in 15 patients. Anti-Scl 70 antibodies were present in 13 patients and rheumatoid factor and ACPA antibodies were present in eight and seven patients respectively. The main indication to use abatacept was joint involvement (59%) followed by myositis (26%). A total of 16 adverse effects were reported in 28 months of abatacept treatment including five that required hospitalization. Most of them occurred in the first 3 months after starting abatacept. After 12 months, the number of tender and swollen joints decreased compared to baseline (p<0.03 and p<0.02 respectively). Moreover, a beneficial effect of abatacept on HAQ-DI at 3 and 6 months (p<0.05) and on morning stiffness at 6 and 12 months (p<0.03) was observed. We also observed a decrease in the modified Rodnan skin score (p<0.05). No changes in lung or gastrointestinal involvement were found. CONCLUSIONS: ABA demonstrated a good safety profile and seems to have some effectiveness on joint involvement and related disability in SSc patients treated in routine care.
OBJECTIVE: To analyze the safety and effectiveness of abatacept (ABA) given in routine care to patients with systemic sclerosis (SSc). METHODS: Retrospective multicenter observational study that enrolled patients with SSc treated with ABA. We collected epidemiological data and clinical outcomes. First, we analyzed the frequency of adverse effects. Secondly, we compared the evolution of different organ manifestations during ABA treatment. We collected data from 6 months before start of therapy to the last follow-up the following parameters: modified Rodnan Skin Score (mRSS), joints, lung and gastrointestinal involvement, concomitant medications, and laboratory tests. RESULTS: Data on twenty-seven patients with SSc were collected (93% females; 67% limited SSc). Rheumatoid arthritis was the most frequent concomitant autoimmune disease. ILD was present in 15 patients. Anti-Scl 70 antibodies were present in 13 patients and rheumatoid factor and ACPA antibodies were present in eight and seven patients respectively. The main indication to use abatacept was joint involvement (59%) followed by myositis (26%). A total of 16 adverse effects were reported in 28 months of abatacept treatment including five that required hospitalization. Most of them occurred in the first 3 months after starting abatacept. After 12 months, the number of tender and swollen joints decreased compared to baseline (p<0.03 and p<0.02 respectively). Moreover, a beneficial effect of abatacept on HAQ-DI at 3 and 6 months (p<0.05) and on morning stiffness at 6 and 12 months (p<0.03) was observed. We also observed a decrease in the modified Rodnan skin score (p<0.05). No changes in lung or gastrointestinal involvement were found. CONCLUSIONS: ABA demonstrated a good safety profile and seems to have some effectiveness on joint involvement and related disability in SScpatients treated in routine care.
Authors: Hana Štorkánová; Sabína Oreská; Maja Špiritović; Barbora Heřmánková; Kristýna Bubová; Martin Komarc; Karel Pavelka; Jiří Vencovský; Jörg H W Distler; Ladislav Šenolt; Radim Bečvář; Michal Tomčík Journal: Sci Rep Date: 2021-01-07 Impact factor: 4.379
Authors: Natalia Mena-Vázquez; Marta Rojas-Gimenez; Clara Fuego-Varela; Aimara García-Studer; Nair Perez-Gómez; Carmen María Romero-Barco; Francisco Javier Godoy-Navarrete; Sara Manrique-Arija; Myriam Gandía-Martínez; Jerusalem Calvo-Gutiérrez; Pilar Morales-Garrido; Coral Mouriño-Rodriguez; Patricia Castro-Pérez; Isabel Añón-Oñate; Francisco Espildora; María Carmen Aguilar-Hurtado; Ana Hidalgo Conde; Rocío Arnedo Díez de Los Ríos; Eva Cabrera César; Rocío Redondo-Rodriguez; María Luisa Velloso-Feijoo; Antonio Fernández-Nebro Journal: Biomedicines Date: 2022-06-22